  
|
|
 |  |  |  |  |  |  |  |  |
|
Drugs & Devices
|
|
|
BOSTON – Ablation bested antiarrhythmic drugs at reducing the incidence of time to first recurrence of atrial arrhythmias in patients with paroxysmal atrial fibrillation, results of a randomized, multicenter trial showed. In the study, radiofrequency catheter–based pulmonary vein isolation was... »
Independent Study Confirms Higher Riata ICD Lead Failure Rate
BOSTON – An independent investigation by seven U.S. centers has shown that recently recalled Riata implantable cardioverter defibrillator leads are significantly more prone to failure than are leads made by a different manufacturer. A retrospective study of all patients older than 18 years who... »
Warfarin Self-Testing Boosts Time in Therapeutic Range
CHICAGO – The new oral anticoagulants for stroke prevention in atrial fibrillation may be garnering all the buzz, but don’t count out warfarin. "It’s not just a knee-jerk reaction that all patients should be switched to the new agents. It’s dependent upon how well you as a physician are... »
BOSTON – Ablation bested antiarrhythmic drugs at reducing the incidence of time to first recurrence of atrial arrhythmias in patients with paroxysmal atrial fibrillation, results of a randomized, multicenter trial... »
Independent Study Confirms Higher Riata ICD Lead Failure Rate
BOSTON – An independent investigation by seven U.S. centers has shown that recently recalled Riata implantable cardioverter defibrillator leads are significantly more prone to failure than are leads made by a different... »
Warfarin Self-Testing Boosts Time in Therapeutic Range
CHICAGO – The new oral anticoagulants for stroke prevention in atrial fibrillation may be garnering all the buzz, but don’t count out warfarin. "It’s not just a knee-jerk reaction that all patients should be switched... »
CHICAGO – An investigational fully human monoclonal antibody slashed low-density lipoprotein cholesterol levels by up to 72% in a phase II clinical trial in dyslipidemic patients not at goal despite already being on a... »
Vorapaxar Cuts Cardiovascular Events but Boosts Bleeding
CHICAGO – Vorapaxar, a new type of platelet inhibitor drug, showed unequivocal efficacy for preventing new cardiovascular events in patients with a history of myocardial infarction, stroke, or peripheral artery disease... »
| May 21 - 25 Sarasota, FL | American Medical Seminars: Cardiology Update in Primary Care |
| Jun 9 - 12 Vancouver, | World Society for Cardio-Thoracic Surgeons (WSCTS): 22nd World Congress |
| Jun 12 London, | Bypass, Balloon Pumps and Circulatory Support |
| Jun 14 - 15 Montreal, | Montreal Heart Institute: Interventional Cardiology Symposium |
| Jun 14 - 24 Departs Copenhagen, | Primary Care Update: Cardiac Health, Metabolic Syndrome, Obesity and Related Disorders |
| Jun 28 - 30 Frankfurt, | Congenital and Structural Interventions (CSI 2012) |
| Jun 30 - Jul 3 National Harbor, MD | American Society of Echocardiography (ASE): Annual Scientific Sessions |
| Jul 27 - 30 Toronto, | International Academy of Cardiology: World Congress on Heart Disease |
| Aug 10 - 13 Jackson Hole, WY | Saint Joseph's Hospital: Annual Tutorials in the Tetons |
| Aug 16 - 19 South Bank, | Cardiac Society of Australia & New Zealand (CSANZ): Annual Scientific Meeting |